WO2019078697A8 - 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물 - Google Patents

항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물

Info

Publication number
WO2019078697A8
WO2019078697A8 PCT/KR2018/012492 KR2018012492W WO2019078697A8 WO 2019078697 A8 WO2019078697 A8 WO 2019078697A8 KR 2018012492 W KR2018012492 W KR 2018012492W WO 2019078697 A8 WO2019078697 A8 WO 2019078697A8
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
pharmaceutical composition
same
cancer treatment
treatment
Prior art date
Application number
PCT/KR2018/012492
Other languages
English (en)
French (fr)
Other versions
WO2019078697A2 (ko
WO2019078697A3 (ko
Inventor
김기수
정준홍
윤애란
송은정
최혜지
임옥재
이윤정
임형권
원종화
Original Assignee
주식회사 녹십자
재단법인 목암생명과학연구소
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SG11202003273PA priority Critical patent/SG11202003273PA/en
Priority to US16/754,431 priority patent/US11498965B2/en
Priority to JP2020521940A priority patent/JP7024072B2/ja
Priority to CN201880068391.7A priority patent/CN111315779B/zh
Application filed by 주식회사 녹십자, 재단법인 목암생명과학연구소 filed Critical 주식회사 녹십자
Priority to EP18867685.2A priority patent/EP3699192A4/en
Priority to EA202090944A priority patent/EA202090944A1/ru
Priority to AU2018353787A priority patent/AU2018353787B2/en
Priority to MX2020003947A priority patent/MX2020003947A/es
Priority to CA3077007A priority patent/CA3077007C/en
Priority to BR112020007770-4A priority patent/BR112020007770A2/pt
Publication of WO2019078697A2 publication Critical patent/WO2019078697A2/ko
Publication of WO2019078697A3 publication Critical patent/WO2019078697A3/ko
Publication of WO2019078697A8 publication Critical patent/WO2019078697A8/ko
Priority to IL274007A priority patent/IL274007A/en
Priority to US17/958,995 priority patent/US20230192851A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 항-CD3 항체 및 이를 포함하는 암 치료용 약학적 조성물에 관한 것이다. 본 발명의 항체는 CD3에 대한 높은 친화도 (affinity) 및 특이성 (specificity)을 가지므로, 암의 예방 또는 치료에 효과적으로 사용될 수 있다.
PCT/KR2018/012492 2017-10-20 2018-10-22 항" cd3항체 및 이를포함하는 암치료용 약학적 조성물 WO2019078697A2 (ko)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EA202090944A EA202090944A1 (ru) 2017-10-20 2018-10-22 Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
JP2020521940A JP7024072B2 (ja) 2017-10-20 2018-10-22 抗ｃｄ３抗体およびそれを含む癌処置用医薬組成物
CN201880068391.7A CN111315779B (zh) 2017-10-20 2018-10-22 抗-cd3抗体及包含其的用于癌症治疗的药物组合物
MX2020003947A MX2020003947A (es) 2017-10-20 2018-10-22 Anticuerpo anti-cd3 y composicion farmaceutica para el tratamiento del cancer que comprende el mismo.
EP18867685.2A EP3699192A4 (en) 2017-10-20 2018-10-22 ANTI-CD3 ANTIBODIES AND PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT WITH IT
US16/754,431 US11498965B2 (en) 2017-10-20 2018-10-22 Anti-CD3 antibody and pharmaceutical composition for cancer treatment comprising same
AU2018353787A AU2018353787B2 (en) 2017-10-20 2018-10-22 Anti-CD3 antibody and pharmaceutical composition for cancer treatment comprising same
SG11202003273PA SG11202003273PA (en) 2017-10-20 2018-10-22 Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same
CA3077007A CA3077007C (en) 2017-10-20 2018-10-22 Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same
BR112020007770-4A BR112020007770A2 (pt) 2017-10-20 2018-10-22 anticorpo anti-cd3, uso do mesmo para prevenção ou tratamento de câncer, composição farmacêutica compreendendo dito anticorpo, polinucleotídeo, vetor de expressão, célula hospedeira e método para produção de um anticorpo que se liga especificamente ao cd3
IL274007A IL274007A (en) 2017-10-20 2020-04-16 Anti-CD3 antibody and a pharmaceutical preparation containing it for the treatment of cancer
US17/958,995 US20230192851A1 (en) 2017-10-20 2022-10-03 Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0136564 2017-10-20
KR1020170136564A KR101973060B1 (ko) 2017-10-20 2017-10-20 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/754,431 A-371-Of-International US11498965B2 (en) 2017-10-20 2018-10-22 Anti-CD3 antibody and pharmaceutical composition for cancer treatment comprising same
US17/958,995 Division US20230192851A1 (en) 2017-10-20 2022-10-03 Anti-cd3 antibody and pharmaceutical composition for cancer treatment comprising same

Publications (3)

Publication Number Publication Date
WO2019078697A2 WO2019078697A2 (ko) 2019-04-25
WO2019078697A3 WO2019078697A3 (ko) 2019-07-04
WO2019078697A8 true WO2019078697A8 (ko) 2020-04-09

Family

ID=66173409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/012492 WO2019078697A2 (ko) 2017-10-20 2018-10-22 항" cd3항체 및 이를포함하는 암치료용 약학적 조성물

Country Status (13)

Country Link
US (2) US11498965B2 (ko)
EP (1) EP3699192A4 (ko)
JP (1) JP7024072B2 (ko)
KR (1) KR101973060B1 (ko)
CN (1) CN111315779B (ko)
AU (1) AU2018353787B2 (ko)
BR (1) BR112020007770A2 (ko)
CA (1) CA3077007C (ko)
EA (1) EA202090944A1 (ko)
IL (1) IL274007A (ko)
MX (1) MX2020003947A (ko)
SG (1) SG11202003273PA (ko)
WO (1) WO2019078697A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020236797A1 (en) * 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
CA3196933A1 (en) * 2020-09-29 2022-04-07 Innovent Biologics (Suzhou) Co., Ltd. Anti-cd3 antibody and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003243138A1 (en) * 2002-03-26 2003-10-13 Trubion Pharmaceuticals, Inc. Activation of tumor-reactive lymphocytes via antibodies or genes recognizing cd3 or 4-1bb
AU2006301492B2 (en) 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
CN103842383B (zh) * 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
ME03440B (me) * 2011-05-21 2020-01-20 Macrogenics Inc Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP3693385A1 (en) * 2013-07-05 2020-08-12 Genmab A/S Humanized or chimeric cd3 antibodies
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
ES2811923T3 (es) * 2013-12-17 2021-03-15 Genentech Inc Anticuerpos anti-CD3 y métodos de uso
JP2017520575A (ja) * 2014-07-01 2017-07-27 ファイザー・インク 二重特異的ヘテロ二量体ダイアボディおよびその使用
EP2982693A1 (en) * 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
CN109069635B (zh) 2016-02-04 2023-09-26 斯克利普斯研究所 人源化抗cd3抗体、偶联物及其用途
KR102329635B1 (ko) * 2017-04-24 2021-11-22 재단법인 목암생명과학연구소 Her3 및 cd3에 결합하는 이중특이적 항체

Also Published As

Publication number Publication date
AU2018353787B2 (en) 2022-02-24
KR101973060B1 (ko) 2019-04-26
EP3699192A4 (en) 2021-10-20
US20200317779A1 (en) 2020-10-08
WO2019078697A2 (ko) 2019-04-25
JP7024072B2 (ja) 2022-02-22
EA202090944A1 (ru) 2020-07-16
US11498965B2 (en) 2022-11-15
CA3077007A1 (en) 2019-04-25
SG11202003273PA (en) 2020-05-28
MX2020003947A (es) 2020-08-03
CN111315779A (zh) 2020-06-19
WO2019078697A3 (ko) 2019-07-04
BR112020007770A2 (pt) 2020-10-20
JP2021501571A (ja) 2021-01-21
CA3077007C (en) 2023-04-18
US20230192851A1 (en) 2023-06-22
AU2018353787A1 (en) 2020-05-21
CN111315779B (zh) 2024-06-21
IL274007A (en) 2020-05-31
EP3699192A2 (en) 2020-08-26

Similar Documents

Publication Publication Date Title
WO2019224716A3 (en) Antibodies specific for gucy2c and uses thereof
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
MY195110A (en) Antibodies to PD-1 and uses Thereof
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
PH12021550152A1 (en) Anti-cd112r compositions and methods
MX2018016364A (es) Anticuerpos anti-pd-l1.
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12016501680B1 (en) Anti-egfrviii antibodies and uses thereof
JOP20190013A1 (ar) أجسام مضادة لـ (تي آي ام -3)
PH12020500225A1 (en) Anti- cd137 antibodies
WO2018191548A3 (en) Complement factor d antagonist antibodies and conjugates thereof
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
MY184628A (en) Afucosylated anti-fgfr2iiib antibodies
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
PH12020550964A1 (en) Heavy chain antibodies binding to cd22
SA519401424B1 (ar) Cmet عوامل ربط أحادية النسيلة، مترافقات عقار منها واستخداماتها
WO2019078698A3 (ko) 항 -msln항체 및 이를포함하는 암치료용 약학적 조성물
PH12019550194A1 (en) Anti-ceacam1 antibody and use thereof
WO2019078697A3 (ko) 항" cd3항체 및 이를포함하는 암치료용 약학적 조성물
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18867685

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3077007

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020521940

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018353787

Country of ref document: AU

Date of ref document: 20181022

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018867685

Country of ref document: EP

Effective date: 20200520

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020007770

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112020007770

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200417